An air-liquid interface exposes the upper surface of cultured airway epithelial cells to air while maintaining controlled support below. This arrangement promotes cellular differentiation and enables functions such as mucus production and ciliary activity. As a result, the model more closely reflects airway behavior relevant to studying responses to inhaled substances, pathogens, inflammation, and therapeutic compounds.
Mucus production and ciliary function provide measurable indicators of epithelial differentiation and airway performance. Changes in these features can reveal how an inhaled substance, pathogen, or treatment affects the tissue. Including both properties therefore helps bioengineers assess airway responses in a controlled setting rather than examining exposure effects through a single biological readout.
These models allow researchers to vary the biological challenge or treatment while maintaining controlled culture conditions. They can examine interactions between airway tissues and inhaled substances, pathogens, inflammatory stimuli, or therapeutic compounds. Comparing the resulting airway responses supports investigation of respiratory disease mechanisms, toxicology, drug delivery, and treatment performance within an engineered experimental platform.
Bronchial nasal models provide a controllable human airway platform that can be used without relying solely on animal studies. Researchers can expose cultured airway cells to defined substances, pathogens, or therapies and observe tissue-level responses under laboratory conditions. This complements other approaches by supporting focused respiratory experiments while preserving relevant epithelial functions such as mucus production and ciliary activity.
A typical workflow begins by culturing airway epithelial cells under controlled conditions and, when appropriate, establishing an air-liquid interface to support differentiation. Researchers then expose the engineered airway tissue to a selected inhaled substance, pathogen, inflammatory challenge, or therapeutic compound. They evaluate resulting airway responses, including changes associated with epithelial function, to address a defined research question.
The systems support several application areas, including respiratory infection studies, inflammation research, toxicology, drug delivery, and therapeutic development. They can also contribute to personalized medicine by providing a platform for examining airway responses in a controlled experimental context. Their value comes from connecting engineered tissue behavior with questions about disease, exposure, and treatment.